Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Ribociclib (Kisqali) for Advanced or Metastatic Breast Cancer
(Open for Input on Submission until October 31, 2017)

Inotuzumab Ozogamicin (Besponsa) for Acute Lymphoblastic Leukemia
(Pending Submission as of October 16, 2017)

Regorafenib (Stivarga) for Unresectable Hepatocellular Carcinoma
(Open for Input on Submission until October 26, 2017)

Avelumab (Brand Name: TBD) for metastatic Merkel Cell Carcinoma
(Open for Input on Submission until October 24, 2017)

Cabozantinib (Brand Name: TBD) for Advanced Renal Cell Carcinoma 
(Open for Input on Submission until October 23, 2017)

Nivolumab (Opdivo) in combination with Ipilimumab (Yervoy) for Metastatic Melanoma
(Open for Feedback on Recommendation until October 20, 2017)

Trifluridine and Tipiracil (Lonsurf) for Metastatic Colorectal Cancer
(Pending Submission as of October 5, 2017)

Olaratumab (Brand Name: TBD) for Advanced Soft Tissue Sarcoma
(Pending Submission as of August 22, 2017)

 

Find a Drug Review